Clinical benefit of response in chronic graft-versus-host disease.

[1]  B. Kurland,et al.  Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. , 2012, Blood.

[2]  B. Kurland,et al.  Validation of measurement scales in ocular graft-versus-host disease. , 2012, Ophthalmology.

[3]  B. Kurland,et al.  Recommended Measures for Joint Chronic GVHD: Results from the Chronic GVHD Consortium , 2012 .

[4]  B. Kurland,et al.  Measurement of Oral Chronic Graft-Versus-Host Disease , 2012 .

[5]  D. Parenti,et al.  Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  Li Li,et al.  A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  B. Kurland,et al.  Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium , 2011, Haematologica.

[8]  Stephanie J. Lee,et al.  Treatment of chronic graft-versus-host disease: Past, present and future , 2011, The Korean journal of hematology.

[9]  P. Herzberg,et al.  Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  Stephanie J. Lee,et al.  Patient-reported outcomes for acute graft-versus-host disease prevention and treatment trials. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  A. Gabrielli,et al.  Imatinib for refractory chronic graft-versus-host disease with fibrotic features. , 2009, Blood.

[12]  B. Storer,et al.  Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. , 2009, Blood.

[13]  H. Jim,et al.  Quality of life after allogeneic hematopoietic cell transplantation. , 2009, Blood.

[14]  J. Radich,et al.  End points to establish the efficacy of new agents in the treatment of acute leukemia. , 2007, Blood.

[15]  U. S. Department of Health and Human Services FDA Cen Research,et al.  Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance , 2006, Health and quality of life outcomes.

[16]  J. Ritz,et al.  Rituximab for steroid-refractory chronic graft-versus-host disease. , 2006, Blood.

[17]  S. Hirschfeld,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  L. Gerber,et al.  Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  K. Ness,et al.  Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. , 2005, Blood.

[20]  G. Vogelsang,et al.  Chronic graft versus host disease , 2004, British journal of haematology.

[21]  J. Apperley,et al.  Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. , 2003, Blood.

[22]  G. Norman,et al.  Is it simple or simplistic? , 2003, Medical care.

[23]  G. Norman,et al.  Interpretation of Changes in Health-related Quality of Life: The Remarkable Universality of Half a Standard Deviation , 2003, Medical care.

[24]  Richard Pazdur,et al.  End points and United States Food and Drug Administration approval of oncology drugs. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Cook,et al.  Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  M. Minden,et al.  Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[28]  J. Larson.  The MOS 36-Item Short form Health Survey , 1997, Evaluation & the health professions.

[29]  A. Bonomi,et al.  Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale , 1997, Bone Marrow Transplantation.

[30]  C. McHorney,et al.  The MOS 36‐Item Short‐Form Health Survey (SF‐36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs , 1993, Medical care.

[31]  Stephanie J. Lee.  Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[32]  B. Storer,et al.  Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[33]  P. Lachenbruch,et al.  Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[34]  M. Turner,et al.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[35]  C. Cleeland,et al.  Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. , 2000, Cancer.

[36]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.